Cost-effectiveness of ten commonly used antipsychotics in first-episode schizophrenia in the UK: economic evaluation based on a <i>de novo</i> discrete event simulation model
Our findings suggest amisulpride (or risperidone-LAI where oral treatment is inappropriate) as the best overall first-line option based on QALYs and cost-effectiveness. Our ranking may be used to guide decision-making between antipsychotics. Our model is open source and could be applied to the other settings.
Authors
- Apostolos Tsiachristas (ORCID: https://orcid.org/0000-0002-4662-8915)
- Mondher Toumi (ORCID: https://orcid.org/0000-0001-7939-7204)
- A. Millier
- Ryan C. Williams (ORCID: https://orcid.org/0000-0001-8486-4903)
- Samuel Aballéa (ORCID: https://orcid.org/0000-0002-6037-2039)
- Belinda Lennox (ORCID: https://orcid.org/0000-0002-4972-8786)
- Huajie Jin (ORCID: https://orcid.org/0000-0002-3872-3998)
- Junwen Zhou (ORCID: https://orcid.org/0000-0002-6812-0944)
- C. François (ORCID: https://orcid.org/0000-0003-2278-3352)
Institutions
- King's College London (GB)
- Peking University (CN)
- Aix-Marseille Université (FR)
- University of Oxford (GB)
- University College London (GB)
- Imperial College London (GB)
Publication Details
- Journal
- The British Journal of Psychiatry
- Published
- 2024-12-25
- DOI
- https://doi.org/10.1192/bjp.2024.251
- Citations
- 1
- Primary Topic
- Health Systems, Economic Evaluations, Quality of Life
- Type
- article
- Field-Weighted Citation Impact
- 1.13
Funders
- Imperial College London
- King's College London
- University College London
- University of Oxford
- Peking University